A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Azacitidine (Primary) ; Dociparstat sodium (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 11 Apr 2017 Planned End Date changed from 31 Mar 2022 to 30 Apr 2022.
- 11 Apr 2017 Planned primary completion date changed from 31 Oct 2019 to 30 Nov 2019.
- 11 Apr 2017 Status changed from not yet recruiting to recruiting.